Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Jonesteller CL[original query] |
---|
Effectiveness of rotavirus vaccination: a systematic review of the first decade of global post-licensure data, 2006-2016
Jonesteller CL , Burnett E , Yen C , Tate JE , Parashar UD . Clin Infect Dis 2017 65 (5) 840-850 Two rotavirus vaccines, Rotarix (RV1) and RotaTeq (RV5), were licensed for global use in 2006. A systematic review of 48 peer-reviewed articles with post-licensure data from 24 countries showed a median RV1 vaccine effectiveness (VE) of 84%, 75%, and 57% in low, medium, and high child mortality countries, respectively, and RV5 VE of 90% in low and 45% in high child mortality countries. A partial vaccine series provided considerable protection, but not to the same level as a full series. VE tended to decline in the second year of life, particularly in medium and high mortality settings, and tended to be greater against more severe rotavirus disease. Post-licensure data from countries across geographic regions and with different child mortality levels demonstrate that under routine use, both RV1 and RV5 are effective against rotavirus disease, supporting the WHO recommendation that all countries introduce rotavirus vaccine into their national immunization program. |
Global impact of rotavirus vaccination on childhood hospitalizations and mortality from diarrhea
Burnett E , Jonesteller CL , Tate JE , Yen C , Parashar UD . J Infect Dis 2017 215 (11) 1666-1672 In 2006, two rotavirus vaccines were licensed. We summarize the impact of rotavirus vaccination on hospitalizations and deaths from rotavirus and all-cause acute gastroenteritis (AGE) during the first 10 years since vaccine licensure, including recent evidence from high child mortality countries. We used standardized guidelines (PRISMA) guidelines to identify observational evaluations of rotavirus vaccine impact among children <5 years of age that presented at least 12 months of pre- and post-vaccine introduction surveillance data. We identified 57 articles from 27 countries. Among children <5 years of age, the median percent reduction in AGE hospitalizations was 38% overall and 41%, 30%, 46% in low, medium, and high child mortality countries, respectively. Hospitalizations and ED visits due to rotavirus AGE were reduced by a median of 67% overall and 71%, 59%, and 60% in low, medium and high child mortality countries, respectively. Implementation of rotavirus vaccines has substantially decreased hospitalizations from rotavirus and all-cause AGE. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure